| Date | Title | Description | |
|---|---|---|---|
| 25 Mar 2025 | On business and financial situation | The Company releases the presentation related to its strategy update because of its 2025 Capital Markets Day | Download |
| 25 Feb 2025 | On P&L | The Company releases the press release related to the full year 2024 financial results | Download |
| 25 Feb 2025 | On P&L | The Company releases the full year 2024 financial results presentation | Download |
| 25 Feb 2025 | About Corporate Governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 07 Feb 2025 | On P&L | The Company informs on some of the results expected by the market consensus | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 21 Oct 2021 | Liquidity and counterparty agreements | Download | |
| 21 Oct 2021 | On business and financial situation | The Company informs of the delay in the decision on Risperidone ISM® by the U.S. Food and Drug Administration (“FDA”). | Download |
| 07 Oct 2021 | Liquidity and counterparty agreements | Download | |
| 04 Oct 2021 | Liquidity and counterparty agreements | Download | |
| 01 Sep 2021 | On business and financial situation | ROVI informs about the joint statement from Moderna and Takeda on the investigation of suspended lots of the vaccine | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 27 Feb 2014 | Informe anual de remuneraciones de consejeros 2013 | Download | |
| 27 Nov 2013 | Acuerdos estratégicos con terceros | Download | |
| 26 Nov 2013 | Acuerdos estratégicos con terceros | Download | |
| 07 Nov 2013 | Información sobre resultados (4) | Download | |
| 07 Nov 2013 | Información sobre resultados (3) | Download |